Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
CHUN CAN CAPITAL GROUP	CNCN	OTC Markets	0	1.6 USD	Stock
WAI CHUN GROUP HOLDINGS LIMITED	1013	Hong Kong S.E.	1,538	0.175 HKD	Stock
ZHANG XIAOQUAN INC.	301055	Shenzhen S.E.	1,670,541	13.6 CNY	Stock
ZHI SHENG GROUP HOLDINGS LIMITED	8370	Hong Kong S.E.	-	0.42 HKD	Stock
WAI CHUN BIO-TECHNOLOGY LIMITED	660	Hong Kong S.E.	128,677	0.135 HKD	Stock
YI CHUN GREEN TECHNOLOGY CO., LTD.	6912	Taipei Exchange	259,322	10.25 TWD	Stock
HA U DONG CHUN CO., LTD.	A233990	Korea S.E.	1,944	533 KRW	Stock
SAM CHUN DANG PHARM. CO., LTD	A000250	Korea S.E.	826,310	112,300 KRW	Stock
CHUN YU WORKS & CO., LTD.	2012	Taiwan S.E.	55,114	24.4 TWD	Stock
CHUN YUAN STEEL INDUSTRY CO., LTD.	2010	Taiwan S.E.	2,139,063	21.15 TWD	Stock

See all

News (135)

Ferrotec : Notice of the Fifth Issuance of New Shares through Third-Party Allotment by Subsidiary that Manufactures Insulated Heat Dissipating Substrates for Power Semiconductors picture_as	22-12-12	PU
Yieh Phui : announces that the board of directors has approved the lifting of the non-compete clause for the management	22-07-06	PU
Shanghai Junshi Biosciences Announces Appointment of Independent Non-Executive Director and Change in Composition of the Nomination Committee And the Remuneration and Appraisal Committee	21-12-16	CI
Shanghai Junshi Biosciences Co., Ltd Announces Executive Changes	21-06-29	CI
China Southern Airlines : THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION (Form 6-K)	21-05-28	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - JS103 INJECTION RECEIVED THE CLINICAL TRIAL APPROVAL	21-05-12	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - PD-1/TGF-BETA BIFUNCTIONAL FUSION PROTEIN JS201 INJECTION RECEIVED THE CLINICAL TRIAL APPROVAL	21-05-07	PU
China Qinfa : MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF A VESSEL	21-04-29	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT / INSIDE INFORMATION - SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 2021 FIRST QUARTERLY REPORT	21-04-29	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - XPO1 INHIBITOR JS110 RECEIVED THE CLINICAL TRIAL APPROVAL	21-04-26	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - TORIPALIMAB PLUS CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADVANCED OR METASTATIC ESOPHAGEAL CANCER REACHED PRIMARY ENDPOINTS IN A PHASE III CLINICAL STUDY	21-04-22	PU
Great Wall Motor : ON UNLOCKING AND LISTING OF THE FIRST TRANCHE OF RESTRICTED SHARES UNDER THE FIRST GRANT OF THE 2020 RESTRICTED SHARE AND SHARE OPTION INCENTIVE SCHEME	21-04-21	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - APPROVAL GRANTED TO SUPPLEMENTAL NEW DRUG APPLICATION FOR TORIPALIMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO FAILED PLATINUM-CONTAINING CHEMOTHERAPY	21-04-12	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - JS007 INJECTION RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION	21-04-07	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2020 ANNUAL RESULTS BRIEFING	21-03-31	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON APPOINTMENT OF SECURITIES AFFAIRS REPRESENTATIVE	21-03-30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON INVESTMENT IN ANWITA AND RELATED PARTY TRANSACTION	21-03-30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON RE-ELECTION OF THE NEW SESSION OF THE BOARD OF SUPERVISORS	21-03-30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON RE-ELECTION OF THE NEW SESSION OF THE BOARD OF DIRECTORS	21-03-30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON ADDITION OF ESTIMATED EXTERNAL GUARANTEE QUOTA FOR 2021	21-03-30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE TEMPORARY REPLENISHMENT OF LIQUIDITY BY USING PART OF THE IDLE PROCEEDS	21-03-30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD. SPECIAL REPORT ON THE DEPOSIT AND ACTUAL USE OF PROCEEDS FOR THE YEAR OF 2020	21-03-30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RESOLUTIONS OF THE THIRTY-FOURTH MEETING OF THE SECOND SESSION OF THE BOARD OF DIRECTORS	21-03-30	PU
Shanghai Junshi Biosciences : CHANGE OF REGISTERED ADDRESS IN THE PRC AND OTHER PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION, THE RULES OF PROCEDURES OF THE GENERAL MEETINGS, THE BOARD OF DIRECTORS AND THE BOARD OF SUPERVISORS	21-03-30	PU
Shanghai Junshi Biosciences : NOTICE OF THE 2021 FIRST CLASS MEETING OF H SHAREHOLDERS	21-03-30	PU
Shanghai Junshi Biosciences : FORM OF PROXY FOR THE 2020 ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 29 JUNE 2021	21-03-30	PU
Shanghai Junshi Biosciences : NOTICE OF THE 2020 ANNUAL GENERAL MEETING	21-03-30	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - TORIPALIMAB HAS BEEN INCLUDED IN DRUG LIST OF THE PROCEDURE FOR BREAKTHROUGH THERAPY DESIGNATION	21-03-24	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - JS103 INJECTION RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION	21-03-05	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - INITIATING ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR TORIPALIMAB WITH FDA FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA	21-03-03	PU
Modern Land China : UNAUDITED OPERATING STATISTICS FOR THE TWO MONTHS ENDED 28 FEBRUARY 2021	21-03-02	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE PROMOTION AGREEMENT WITH ASTRAZENECA PHARMACEUTICAL	21-02-28	PU
Shanghai Junshi Biosciences : INSIDE INFORMATION - 2020 PRELIMINARY RESULTS ANNOUNCEMENT	21-02-26	PU
Shenyang Public Utility : MAJOR TRANSACTION RELATING TO ACQUISITION OF THE PROPERTIES WITH ADVANCE TO AN ENTITY AND NOTICE OF EXTRAORDINARY GENERAL MEETING	21-02-26	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - PD-1/TGF-BETA BIFUNCTIONAL FUSION PROTEIN JS201 INJECTION RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION	21-02-24	PU
Beijing Easpring Material Technology CO.,LTD. completed the acquisition of remaining 31.25% stake in Easpring Technology New Materials Co., Ltd. from BGRIMM Technology Group Co., Ltd.	20-12-27	CI
Shanghai Junshi Biosciences Co., Ltd. Announces Change in Independent Non-Executive Director and Change in Composition of the Nomination Committee,The Audit Committee and the Remuneration and Appraisal Committee	20-11-16	CI
EVOC Intelligent Technology : JOINT ANNOUNCEMENT VOLUNTARY ANNOUNCEMENT IN RELATION TO VOLUNTARY CONDITIONAL OFFER BY ICBC INTERNATIONAL CAPITAL LIMITED FOR AND ON BEHALF OF THE OFFEROR TO ACQUIRE ALL OF THE ISSUED H SHARES IN EVOC INTELLIGENT TECHNOLOGY COMPANY LIMITED AND PROPOSED WITHDRAWAL OF LISTING OF THE H SHARES OF EVOC INTELLIGENT TECHNOLOGY COMPANY LIMITED	20-09-18	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - TORIPALIMAB FOR TREATMENT OF SOFT TISSUE SARCOMA IS GRANTED THE ORPHAN-DRUG DESIGNATION BY THE FDA	20-09-17	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE TECHNOLOGY TRANSFER AND COOPERATION AGREEMENT WITH WIGEN BIOMEDICINE	20-09-16	PU
EVOC Intelligent Technology : JOINT ANNOUNCEMENT VOLUNTARY ANNOUNCEMENT IN RELATION TO VOLUNTARY CONDITIONAL OFFER BY ICBC INTERNATIONAL CAPITAL LIMITED FOR AND ON BEHALF OF THE OFFEROR TO ACQUIRE ALL OF THE ISSUED H SHARES IN EVOC INTELLIGENT TECHNOLOGY COMPANY LIMITED AND PROPOSED WITHDRAWAL OF LISTING OF THE H SHARES OF EVOC INTELLIGENT TECHNOLOGY COMPANY LIMITED	20-09-15	PU
EVOC Intelligent Technology : JOINT ANNOUNCEMENT POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING AND THE H SHARE CLASS MEETING IN RELATION TO (1) VOLUNTARY CONDITIONAL OFFER BY ICBC INTERNATIONAL CAPITAL LIMITED FOR AND ON BEHALF OF THE OFFEROR TO ACQUIRE ALL OF THE ISSUED H SHARES IN EVOC INTELLIGENT TECHNOLOGY COMPANY LIMITED AND (2) PROPOSED WITHDRAWAL OF LISTING OF THE H SHARES OF EVOC INTELLIGENT TECHNOLOGY COMPANY LIMITED	20-09-15	PU
Beijing Easpring Material Technology CO.,LTD. entered into a letter of intent to acquire remaining 31.25% stake in Easpring Technology New Materials Co., Ltd. from BGRIMM Technology Group Co., Ltd. for approximately CNY 640 million.	20-09-10	CI
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - UPDATE ON PROGRESS FOR TORIPALIMAB INJECTION	20-09-10	PU
Shanghai Junshi Biosciences : FORMATION OF A JV COMPANY TO JOINTLY DEVELOP CD39 DRUG	20-09-09	PU

1234NextSee all

Companies (24)

WULIANGYE YIBIN CO.,LTD. 84 067 M $

Wuliangye Yibin Co., Ltd. specializes in the production and marketing of liqueurs. Net sales break down by activity as follows: - sale of liquor (91.5%): Wuliangye, Wuliangye 501, Classic Wuliangye, Wuliangye 1618, Wuliang Chun (Spring), Wuliang Chun, Wu ...

ZHANG XIAOQUAN INC. 294 M $

Zhang Xiaoquan Inc is a China-based company mainly engaged in the design, research and development, manufacturing and sales of hardware products and the provision of related services. The Company's main products include scissors, knives, knife-scissors se ...

EAST ASIA HOLDINGS INVESTMENT LIMITED 30 M $

East Asia Holdings Investment Limited is a Hong Kong-based holding company engaged in the management of its subsidiaries. The Company's subsidiaries include Fujian Qiu Zhi Sportswear Co., Ltd and Fujian Quanzhou New East Asia Shoes Co., Ltd. Through its s ...

CHUN YUAN STEEL INDUSTRY CO., LTD. 425 M $

CHUN YUAN STEEL INDUSTRY CO., LTD. is a Taiwan-based company principally engaged in the manufacture, processing and sales of steel plates and related products. The Companyâs products include steel plates, special steel materials, silicon steel sheets, s ...

YI CHUN GREEN TECHNOLOGY CO., LTD. 41 M $

Yi Chun Green Technology Co Ltd is a Taiwan-based company mainly engaged in the recycle of diapers and the sale of recycled raw materials. Fibers, superabsorbent molecules and plastics decomposed from discarded diapers can be supplied to various paper pro ...

ZHANG JIA JIE TOURISM GROUP CO., LTD 363 M $

Zhang Jia Jie Tourism Group Co Ltd is a Chinese company primarily engaged in the tourism business. The Company operates its business through the Travel Agency Segment, Tourist Passenger Transportation Segment, Tourism Segment and Other Segment. The Compan ...

FEIYU TECHNOLOGY INTERNATIONAL COMPANY LTD. 62 M $

Feiyu Technology International Co., Ltd. is an investment holding company principally engaged in the development and operation of mobile games and Web games. The Companyâs principal markets include both domestic market and overseas markets, including Ho ...

CHUN CAN CAPITAL GROUP 352 M $

Chun Can Capital Group. is a non-operating shell company. The Company is serving as a vehicle to effect a merger, exchange of capital stock, asset acquisition, or other business combination with a domestic or foreign private business. The company has no p ...

ZHI SHENG GROUP HOLDINGS LIMITED 5 M $

Zhi Sheng Group Holdings Limited is an investment holding company. The Company and its subsidiaries are principally engaged in the manufacture and sale of office furniture products in the People's Republic of China (PRC). The companyâs products can be c ...

WAI CHUN GROUP HOLDINGS LIMITED 6 M $

Wai Chun Group Holdings Ltd is an investment holding company principally engaged in the trading of chemicals and agricultural products. The Company operates its business through two segments. The General Trading segment is engaged in the trading of chemic ...

123Next

Insiders

Zhi Chun Zhang

Zhi Chun Zhang is currently the Chief Financial Officer & Finance Director at Ping An Insurance (Group) Co. of China Ltd.
and also holds a Director position at Ping An Wanjia Healthcare Investment Management Co.,.
Ltd.
Zhang obtained an undergraduate degree from Shanghai University of Finance & Economics.

Zhi Chun Zhang

Presently, Zhi Chun Zhang is Chairman-Supervisory Board at Beijing Roborock Technology Co., Ltd. He received an undergraduate degree from Hefei University of Technology and a graduate degree from the University of Science & Technology of China.

No results for this search